Indian markets ended the financial year 2017-18 with decent returns. However, there were select stocks from the Nifty that saw massive under performance. Guess what, once the bell weather pharma stocks were the worst hit. Take a look...
Lupin, like most other peer companies was the worst performer from the Nifty. The stock closed 57 per cent lower than its price on April 1, 2017.
This is another pharma stock that has been hit by squeeze in margins from the US business. The stock was down 37 per cent during the course of the financial year. Many analysts have a "buy" call on the stock and expect a recovery in the next couple of years.
Surprisingly, Tata Motors figures in the list of laggards during FY 2017-18. The stock was also down near 37 percent. The fall was despite a sharp recovery in the domestic business of Tata Motors. Most analysts have a "buy" call on the stock as it has hit a new 52-week low.
Sun Pharma is another stock that dropped 38 per cent and was a poor performer in 2017-18. The reasons are almost the same like the two other pharma companies mentioned above.
Dr Reddy's Pharma
Another pharma stock makes it to the list of pharma stocks that were laggards during the financial year. Fortunately, pharma stocks do not have a very high weightage in the index or we would have seen a solid collapse in the index.